Oppenheimer Asset Management Inc. Neurocrine Biosciences Inc Transaction History

Oppenheimer Asset Management Inc.

$6.65 Billion
Q1 2024

A detailed history of Oppenheimer Asset Management Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 13,421 shares of NBIX stock, worth $1.85 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

13,421

Previous 15,477 13.28%

Holding current value

$1.85 Million

Previous $2.04 Million 9.22%

% of portfolio

0.03%

Previous 0.03%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$130.4 - $143.74 $268,102 - $295,529	-2,056 Reduced 13.28%	13,421 $1.85 Million
Q4 2023 Feb 13, 2024	SELL	$106.07 - $132.76 $47,943 - $60,007	-452 Reduced 2.84%	15,477 $2.04 Million
Q3 2023 Nov 07, 2023	BUY	$94.02 - $117.1 $163,218 - $203,285	1,736 Added 12.23%	15,929 $1.79 Million
Q2 2023 Aug 02, 2023	SELL	$89.53 - $104.87 $1.08 Million - $1.26 Million	-12,027 Reduced 45.87%	14,193 $1.34 Million
Q1 2023 May 10, 2023	SELL	$94.11 - $123.02 $18,445 - $24,111	-196 Reduced 0.74%	26,220 $2.65 Million

Q4 2022 Feb 06, 2023	SELL	$106.72 - $127.06 $409,057 - $487,020	-3,833 Reduced 12.67%	26,416 $3.16 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $316,951 - $371,297	-3,444 Reduced 10.22%	30,249 $3.21 Million
Q2 2022 Aug 08, 2022	SELL	$75.79 - $100.07 $69,726 - $92,064	-920 Reduced 2.66%	33,693 $3.29 Million
Q1 2022 May 12, 2022	BUY	$72.45 - $94.81 $592,568 - $775,450	8,179 Added 30.94%	34,613 $3.25 Million
Q4 2021 Feb 02, 2022	SELL	$79.65 - $106.22 $188,133 - $250,891	-2,362 Reduced 8.2%	26,434 $2.25 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $30,507 - $35,056	354 Added 1.24%	28,796 $2.76 Million
Q2 2021 Aug 03, 2021	BUY	$89.43 - $102.27 $60,275 - $68,929	674 Added 2.43%	28,442 $2.77 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $221,727 - $302,320	2,532 Added 10.03%	27,768 $2.7 Million
Q4 2020 Feb 11, 2021	SELL	$86.91 - $108.33 $55,535 - $69,222	-639 Reduced 2.47%	25,236 $2.42 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $1.55 Million - $2.18 Million	16,149 Added 166.04%	25,875 $2.49 Million
Q2 2020 Aug 11, 2020	BUY	$85.09 - $130.36 $66,795 - $102,332	785 Added 8.78%	9,726 $1.19 Million
Q1 2020 May 08, 2020	BUY	$75.11 - $113.76 $103,877 - $157,330	1,383 Added 18.3%	8,941 $774,000
Q4 2019 Feb 07, 2020	BUY	$86.8 - $118.57 $7,117 - $9,722	82 Added 1.1%	7,558 $812,000
Q3 2019 Oct 31, 2019	BUY	$83.82 - $101.5 $17,099 - $20,706	204 Added 2.81%	7,476 $674,000
Q2 2019 Aug 09, 2019	SELL	$72.24 - $91.27 $14,664 - $18,527	-203 Reduced 2.72%	7,272 $614,000
Q1 2019 Apr 24, 2019	BUY	$69.31 - $91.53 $48,517 - $64,071	700 Added 10.33%	7,475 $659,000
Q4 2018 Jan 30, 2019	BUY	$68.32 - $124.36 $462,867 - $842,539	6,775 New	6,775 $484,000

Others Institutions Holding NBIX

# of Institutions

628

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account

Oppenheimer Asset Management Inc. Neurocrine Biosciences Inc Transaction History